The time is now for committed and comprehensive action to attain more broadly protective coronavirus vaccines: The coronavirus vaccines R&D roadmap
- PMID: 36828718
- PMCID: PMC9941882
- DOI: 10.1016/j.vaccine.2023.02.053
The time is now for committed and comprehensive action to attain more broadly protective coronavirus vaccines: The coronavirus vaccines R&D roadmap
Keywords: Broadly protective coronavirus vaccines; COVID-19; Coronavirus; Pandemic preparedness; Roadmap; SARS-CoV-2.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Hamburg reports no competing interests. Dr. Poland declares the following interests: Dr. Poland offers consultative advice on COVID-19 vaccine development to AstraZeneca, Pfizer, Medicago, Johnson&Johnson/Janssen, Novavax, and Moderna. Dr. Poland also has received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine for which he holds a patent. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies.
Similar articles
-
A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy.Vaccine. 2023 Mar 24;41(13):2101-2112. doi: 10.1016/j.vaccine.2023.02.032. Epub 2023 Feb 21. Vaccine. 2023. PMID: 36870874 Free PMC article. Review.
-
A research and development (R&D) roadmap for broadly protective coronavirus vaccines: Setting a path to address coronavirus threats.Vaccine. 2022 Oct 6;40(42):6001-6003. doi: 10.1016/j.vaccine.2022.08.071. Epub 2022 Sep 8. Vaccine. 2022. PMID: 36109277 Free PMC article. No abstract available.
-
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.Science. 2021 Aug 27;373(6558):991-998. doi: 10.1126/science.abi4506. Epub 2021 Jun 22. Science. 2021. PMID: 34214046 Free PMC article.
-
Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines.Front Immunol. 2022 Sep 20;13:952650. doi: 10.3389/fimmu.2022.952650. eCollection 2022. Front Immunol. 2022. PMID: 36203593 Free PMC article.
-
SARS-CoV-2 epitopes inform future vaccination strategies.Front Immunol. 2022 Nov 25;13:1041185. doi: 10.3389/fimmu.2022.1041185. eCollection 2022. Front Immunol. 2022. PMID: 36505475 Free PMC article. Review.
Cited by
-
Protection conferred by booster vaccine doses in hospitalized patients with COVID-19 during the SARS-CoV-2 Omicron BA.2 and BA.5 epidemics from 2022 to 2023 in Greece.Infect Med (Beijing). 2024 Oct 18;3(4):100144. doi: 10.1016/j.imj.2024.100144. eCollection 2024 Dec. Infect Med (Beijing). 2024. PMID: 39624059 Free PMC article.
References
-
- World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int [accessed February 2023].
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous